Biosimilar Clinical Development: Scientific Considerations and New Methodologies (eBook, ePUB)

Redaktion: Barker, Kerry B.; Jin, Bo; Xu, Siyan; D'Agostino Sr., Ralph B.; Menon, Sandeep M.

• Format: ePub

Produktbeschreibung

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Taylor & Francis
• Seitenzahl: 268
• Erscheinungstermin: 25. November 2016
• Englisch
• ISBN-13: 9781315355900
• Artikelnr.: 47381598

Autorenporträt

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer , Dr. Ralph D'Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.

Inhaltsangabe

Biosimilars for Drug Development. Regulatory Requirements on Biosimilars.
System Biology in the Context of Biosimilars. Clinical Considerations on
Biosimilars. Large Molecules Complete Molecular Confidence (CMC)
Development Strategy. Immunogenicity. Interchangeability. Bridging a New
Biologic to Its Reference Biologic. How to Account Covariate Effect to Show
Non-Inferiority in Biosimilars. Novel Method in Inference of Equivalence in
Biosimilars. Multiplicity Adjustment in Equivalence Using Two One-Sided
Tests. Bayesian Methods in Biosimilar Studies.